Coronado
Biosciences Inc. (Nasdaq: CNDO) entered an exclusive license agreement with
NeuPharma to develop and commercialize novel irreversible 3rd Generation
EGFR inhibitors. The stock price leaped $1.45 to $4.67.
Coronado enters exclusive license agreement
March 19, 2015 at 12:49 PM EDT
